布地格福吸入气雾剂治疗中、重度慢性阻塞性肺疾病患者的临床研究

目的 观察布地格福吸入气雾剂治疗中、重度慢性阻塞性肺疾病(COPD)患者的临床疗效与安全性.方法 将150例中、重度COPD患者随机分为对照A组50例、对照B组50例和试验组50例.对照A组给予噻托溴铵粉吸入剂每次18μg,qd,吸入治疗+沙美特罗替卡松每次300μg,bid,吸入治疗;对照B组给予布地奈德福莫特罗每次...

Clinical trial of budegofol inhaled aerosol in the treatment of patients with moderate-to-severe chronic obstructive pulmonary disease

Objective budegofol inhaled aerosol in the treatment of patients with moderate-to-severe chronic obstructive pulmonary disease( COPD). Methods A total of 150 patients with moderate-to-severe COPD were randomly divided into control A,control B and treatment groups with 50 cases per group. Control A group was given tiotropium bromide powder inhalation18 μg per time,qd,inhalation treatment + salmeterol and ticasone 300μg per time,bid,inhalation treatment. Control B group was given budesonide formoterol each time 164. 5-329. 0 μg,bid,inhalation treatment. Treatment group was given budegofol inhalation aerosol 172-344 μg per time,bid,inhalation treatment. Three groups were treated for 6 months. The lung function and adverse drug reactions were compared among three groups. Results A total of 10 cases were shed during the trial process. After 6 months of treatment,the forced vital capacity of treatment,control A and control B groups was( 2. 53 ± 0. 62),( 2. 14 ± 0. 46) and( 2. 03 ± 0. 52) L,the forced expiratory volume in one second was( 1. 54 ± 0. 41),( 1. 32 ± 0. 35) and( 1. 22 ± 0. 44) L. The above indicators of the treatment group were compared with those of control A and control B groups,the differences were statistically significant( all P < 0. 05).The adverse drug reactions of the three groups were upper respiratory tract infection,pneumonia and nasopharyngitis.The incidences of total adverse drug reactions in the treatment,control A and control B groups were 23. 40%,30. 43%and 25. 53% without significant differences( all P > 0. 05). Conclusion Budigefor inhaled aerosol in the treatment of moderate-to-severe COPD can improve lung function more effectively,without increasing the incidence of adverse drug reactions.